EMA clarified that the benefits continue to outweigh the risks of these “very rare” side effects
The European Medicines Agency (EMA) confirmed this Wednesday AstraZeneca’s “possible link” In special cases dAnd blood clotting It has been reported in some people receiving this vaccine, but it is believed that its benefits continue to outweigh the risk of side effects.
According to the conclusion drawn by the EMA Safety Committee (PRAC) today, “Unusual” blood clots Low platelets” should be used as Very rare side effectsThe “AstraZeneca vaccine” is based on “all currently available evidence” and includes recommendations from a special expert group.
EMA experts cannot determine the risk factors for these events, such as age, gender, or past medical history, although “reasonable explanations (for these rare blood clotting cases) are Immune response to vaccines“In some people, PRAC requested new research to try to gather more information and take other necessary measures.
Emer Cooke, executive director of EMA, emphasized at a remote press conference held at the agency’s headquarters in Amsterdam that covid-19 is a “very dangerous disease” and that vaccines are “very important to fight this pandemic”, including AstraZeneca“It has been proven to be very effective against the coronavirus.”
Since there are no clear risk factors, EMA emphasized that “it is important that both vaccinated people and health professionals should be aware of the possibility of illness. Rare cases of blood clotting The blood platelet content is low within two weeks after vaccination.”
So far, most reported cases have occurred in Women under 60 Within 15 days after vaccination.
In total, PRAC conducted an in-depth review 62 cases of venous cerebral thrombosis (CVST) and 24 cases of visceral venous thrombosis, reported until March 22, of which, 18 people are fatal.